Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 26, 2015, 45 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.27 to $183,764,684.16.

Highlighted Stocks Traded by Insiders:

Violin Memory (VMEM) - FREE Research Report

Mahadevan Vivekanand, who is Director at Violin Memory, bought 1,200 shares at $3.61 on March 26, 2015. Following this transaction, the Director owned 1,700 shares meaning that the stake was boosted by 240% with the 1,200-share transaction.

The shares most recently traded at $3.50, down $0.11, or 3.06% since the insider transaction. Historical insider transactions for Violin Memory go as follows:

  • 4-Week # shares bought: 169,925
  • 12-Week # shares bought: 169,925
  • 24-Week # shares bought: 169,925

The average volume for Violin Memory has been 810,500 shares per day over the past 30 days. Violin Memory has a market cap of $331.3 million and is part of the technology sector and computer hardware industry. Shares are down 25.68% year-to-date as of the close of trading on Thursday.

Violin Memory, Inc. develops and supplies memory-based storage systems to bring storage performance in line with high-speed applications, servers, and networks worldwide. Currently, there is 1 analyst who rates Violin Memory a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VMEM - FREE

TheStreet Quant Ratings rates Violin Memory as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full Violin Memory Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Aramark (ARMK) - FREE Research Report

Warburg Pincus Private Equity IX, L.P., who is Director at Aramark, sold 5.7 million shares at $32.16 on March 26, 2015. Following this transaction, the Director owned 14.0 million shares meaning that the stake was reduced by 28.96% with the 5.7 million-share transaction.

The shares most recently traded at $31.39, down $0.77, or 2.45% since the insider transaction. Historical insider transactions for Aramark go as follows:

  • 4-Week # shares sold: 1.0 million
  • 12-Week # shares sold: 8.2 million
  • 24-Week # shares sold: 16.7 million

The average volume for Aramark has been 2.1 million shares per day over the past 30 days. Aramark has a market cap of $7.6 billion and is part of the services sector and leisure industry. Shares are up 1.35% year-to-date as of the close of trading on Thursday.

Aramark provides food, facilities, and uniform services to education, healthcare, business and industry, sports, leisure, and corrections clients primarily in North America. The stock currently has a dividend yield of 1.08%. The company has a P/E ratio of 41.0. Currently, there are 5 analysts who rate Aramark a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARMK - FREE

TheStreet Quant Ratings rates Aramark as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins. Get the full Aramark Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PetMed Express (PETS) - FREE Research Report

Korn Ronald J, who is Director at PetMed Express, sold 2,000 shares at $16.25 on March 26, 2015. Following this transaction, the Director owned 72,333 shares meaning that the stake was reduced by 2.69% with the 2,000-share transaction.

Rosenbloom Bruce S, who is Chief Financial Officer at PetMed Express, sold 500 shares at $16.25 on March 26, 2015. Following this transaction, the Chief Financial Officer owned 45,517 shares meaning that the stake was reduced by 1.09% with the 500-share transaction.

The shares most recently traded at $16.07, down $0.18, or 1.12% since the insider transaction. Historical insider transactions for PetMed Express go as follows:

  • 4-Week # shares sold: 500
  • 12-Week # shares sold: 63,157
  • 24-Week # shares sold: 63,167

The average volume for PetMed Express has been 214,400 shares per day over the past 30 days. PetMed Express has a market cap of $326.6 million and is part of the health care sector and drugs industry. Shares are up 12.11% year-to-date as of the close of trading on Thursday.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats. The stock currently has a dividend yield of 4.22%. The company has a P/E ratio of 19.0. Currently, there are no analysts who rate PetMed Express a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETS - FREE

TheStreet Quant Ratings rates PetMed Express as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full PetMed Express Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null